Kiniksa Pharmaceuticals International (KNSA) Accounts Payables (2017 - 2026)

Kiniksa Pharmaceuticals International's Accounts Payables history runs 10 years deep, the most recent figure standing at $24.4 million for Q1 2026.

• Quarterly Accounts Payables rose 1131.18% year-over-year to $24.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.4 million (up 1131.18% YoY) and the FY2025 annual result came in at $2.0 million, down 0.54% from the prior year.
• Accounts Payables was $24.4 million for Q1 2026 at Kiniksa Pharmaceuticals International, up from $2.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $24.4 million in Q1 2026 and bottomed at $648000.0 in Q2 2023.
• A 5-year average of $5.5 million and a median of $3.4 million in 2022 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables sank 75.27% — and 2026, when it surged 1131.18%.
• Kiniksa Pharmaceuticals International's Accounts Payables stood at $7.9 million in 2022, then grew by 4.39% to $8.2 million in 2023, then sank by 75.27% to $2.0 million in 2024, then retreated by 0.54% to $2.0 million in 2025, then surged by 1103.25% to $24.4 million in 2026.
• Business Quant data shows KNSA's Accounts Payables at $24.4 million in Q1 2026, $2.0 million in Q4 2025, and $6.1 million in Q3 2025.